Irbesartán/Hidroclorotiazida Aurovitas

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartán/Hidroclorotiazida Aurovitas, is an angiotensin II receptor blocker/thiazide diuretic presented as an oral tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Irbesartán/Hidroclorotiazida Aurovitas as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage hypertension, a condition characterized by elevated blood pressure.

- Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. - Hypertension with edema: promotes diuresis to reduce fluid overload while controlling blood pressure. - Hypertension in type 2 diabetes: provides blood pressure control with additional renal protective effects.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia (especially when combined with potassium‑sparing agents) - Angioedema - Severe allergic reactions (rash, Stevens‑Johnson syndrome) - Hepatic dysfunction

Patients should be evaluated for renal function, electrolyte balance, and potential drug interactions before initiating therapy.

- Renal impairment: monitor serum creatinine and adjust dose if needed. - Electrolyte monitoring: check potassium and sodium levels regularly. - Pregnancy: avoid use unless clearly needed, as safety is not established. - Concomitant NSAIDs: may reduce antihypertensive effect and affect renal function. - Gout: monitor uric acid levels, as thiazides can increase serum uric acid. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: increased lithium levels and toxicity. - ACE inhibitors or other ARBs: additive risk of renal dysfunction and hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and impair renal function. - Antidiabetic agents: thiazide component may increase blood glucose. - CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan plasma concentrations.